Published in Curr Neuropharmacol on December 01, 2011
Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts. Crit Rev Toxicol (2014) 0.90
Leptin regulates amyloid β production via the γ-secretase complex. Biochim Biophys Acta (2012) 0.83
Bridging integrator 1 (BIN1) protein expression increases in the Alzheimer's disease brain and correlates with neurofibrillary tangle pathology. J Alzheimers Dis (2014) 0.82
Obesity and diabetes cause cognitive dysfunction in the absence of accelerated β-amyloid deposition in a novel murine model of mixed or vascular dementia. Acta Neuropathol Commun (2014) 0.82
Model Hirano bodies protect against tau-independent and tau-dependent cell death initiated by the amyloid precursor protein intracellular domain. PLoS One (2012) 0.80
Paeonol Suppresses Neuroinflammatory Responses in LPS-Activated Microglia Cells. Inflammation (2016) 0.79
Evidence against a role of P-glycoprotein in the clearance of the Alzheimer's disease Aβ1-42 peptides. Cell Stress Chaperones (2015) 0.75
Molecular Docking and In Silico ADMET Study Reveals Acylguanidine 7a as a Potential Inhibitor of β-Secretase. Adv Bioinformatics (2016) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Autophagy in the pathogenesis of disease. Cell (2008) 34.68
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science (1993) 33.32
Global prevalence of dementia: a Delphi consensus study. Lancet (2005) 23.30
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature (2009) 19.56
Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature (2002) 19.36
Alzheimer's disease: genes, proteins, and therapy. Physiol Rev (2001) 19.19
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci U S A (1985) 16.10
Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature (1998) 15.24
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet (2009) 14.86
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 13.19
Alzheimer's disease. N Engl J Med (2010) 13.13
Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging (1997) 10.81
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet (2008) 8.51
Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun (1984) 8.14
Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol (2009) 7.50
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60. Science (2001) 7.03
Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature (2008) 6.89
Role of genes and environments for explaining Alzheimer disease. Arch Gen Psychiatry (2006) 6.68
Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci (2006) 6.52
Neuropathologic substrate of mild cognitive impairment. Arch Neurol (2006) 6.26
Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J (1985) 6.24
Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (2001) 6.17
Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A (1998) 6.13
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science (2001) 6.00
Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem (2009) 5.76
The role of apolipoprotein E in Alzheimer's disease. Neuron (2009) 5.55
Amyloid beta -protein (Abeta) assembly: Abeta 40 and Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci U S A (2002) 5.46
Obesity in middle age and future risk of dementia: a 27 year longitudinal population based study. BMJ (2005) 5.34
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest (2000) 5.07
Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med (2000) 4.99
Deciphering the molecular basis of memory failure in Alzheimer's disease. Neuron (2004) 4.88
Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathol (2009) 4.73
Metabolic regulation of brain Abeta by neprilysin. Science (2001) 4.47
Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann Neurol (2007) 4.47
Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J Biol Chem (2004) 4.33
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA (2009) 4.02
Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A (2009) 3.86
Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. Proc Natl Acad Sci U S A (2003) 3.85
Risk factors for Alzheimer's disease: a prospective analysis from the Canadian Study of Health and Aging. Am J Epidemiol (2002) 3.85
Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends Neurosci (2005) 3.84
Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron (2005) 3.72
Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA (2009) 3.62
Neural mechanisms of ageing and cognitive decline. Nature (2010) 3.59
The amyloid hypothesis for Alzheimer's disease: a critical reappraisal. J Neurochem (2009) 3.45
Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem (2010) 3.16
Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci U S A (2005) 3.15
Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxib. Arch Neurol (2008) 2.86
Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep (2007) 2.85
Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 2.78
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
Clinicopathologic correlations in a large Alzheimer disease center autopsy cohort: neuritic plaques and neurofibrillary tangles "do count" when staging disease severity. J Neuropathol Exp Neurol (2007) 2.65
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol (2008) 2.62
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol (2009) 2.60
Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord (2002) 2.56
NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies. Neurobiol Aging (2006) 2.55
The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis (2009) 2.54
Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. J Neurosci (2006) 2.47
The intracellular domain of the beta-amyloid precursor protein is stabilized by Fe65 and translocates to the nucleus in a notch-like manner. J Biol Chem (2001) 2.42
AD lesions and infarcts in demented and non-demented Japanese-American men. Ann Neurol (2005) 2.31
Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J Neurosci (2003) 2.28
Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med (1996) 2.04
Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci U S A (2003) 2.02
Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01
A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet (2006) 2.01
Disease-modifying therapies for Alzheimer disease: challenges to early intervention. Neurology (2007) 1.88
When loss is gain: reduced presenilin proteolytic function leads to increased Abeta42/Abeta40. Talking Point on the role of presenilin mutations in Alzheimer disease. EMBO Rep (2007) 1.81
Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol (2009) 1.76
The gamma -secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus. Proc Natl Acad Sci U S A (2001) 1.72
Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med (2007) 1.72
Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging (2005) 1.68
Soluble amyloid oligomers increase bilayer conductance by altering dielectric structure. J Gen Physiol (2006) 1.64
Adiposity, type 2 diabetes, and Alzheimer's disease. J Alzheimers Dis (2009) 1.53
Chemical inducers of autophagy that enhance the clearance of mutant proteins in neurodegenerative diseases. J Biol Chem (2010) 1.50
Leptin receptor action and mechanisms of leptin resistance. Cell Mol Life Sci (2005) 1.49
Human cerebral neuropathology of Type 2 diabetes mellitus. Biochim Biophys Acta (2008) 1.46
FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. Neurobiol Aging (2002) 1.44
Leptin: a novel therapeutic strategy for Alzheimer's disease. J Alzheimers Dis (2009) 1.42
The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet (2010) 1.41
Abeta solubility and deposition during AD progression and in APPxPS-1 knock-in mice. Neurobiol Dis (2007) 1.40
Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging (2001) 1.39
Formation and development of Lewy pathology: a critical update. J Neurol (2009) 1.37
Neprilysin-sensitive synapse-associated amyloid-beta peptide oligomers impair neuronal plasticity and cognitive function. J Biol Chem (2006) 1.37
Mice as models: transgenic approaches and Alzheimer's disease. J Alzheimers Dis (2006) 1.32
Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol (2006) 1.31
Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl (2006) 1.30
Rodent A beta modulates the solubility and distribution of amyloid deposits in transgenic mice. J Biol Chem (2007) 1.27
Mean age of onset in familial Alzheimer's disease is determined by amyloid beta 42. Neurobiol Aging (2005) 1.20
APP transgenic mice Tg2576 accumulate Abeta peptides that are distinct from the chemically modified and insoluble peptides deposited in Alzheimer's disease senile plaques. Biochemistry (2002) 1.18
A two-year study with fibrillar beta-amyloid (Abeta) immunization in aged canines: effects on cognitive function and brain Abeta. J Neurosci (2008) 1.15
Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging (2009) 1.12
Transgenic mouse models of Alzheimer's disease. Mt Sinai J Med (2010) 1.09
Increased extracellular amyloid deposition and neurodegeneration in human amyloid precursor protein transgenic mice deficient in receptor-associated protein. J Neurosci (2002) 1.07
Animal models of amyloid-beta-related pathologies in Alzheimer's disease. FEBS J (2010) 1.06
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
A combined computational-experimental approach predicts human microRNA targets. Genes Dev (2004) 9.82
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement (2012) 5.10
The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci (2008) 4.28
An mRNA m7G cap binding-like motif within human Ago2 represses translation. Cell (2007) 4.03
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res (2004) 2.73
Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol Genet Metab (2007) 2.52
Dicer loss in striatal neurons produces behavioral and neuroanatomical phenotypes in the absence of neurodegeneration. Proc Natl Acad Sci U S A (2008) 2.32
The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases. J Mol Biol (2010) 2.20
GBA mutations increase risk for Lewy body disease with and without Alzheimer disease pathology. Neurology (2012) 2.19
A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci U S A (2002) 1.97
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci (2003) 1.87
Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter. Acta Neuropathol (2010) 1.71
Comparative measurements of hypoxia in human brain tumors using needle electrodes and EF5 binding. Cancer Res (2004) 1.59
miR-107 regulates granulin/progranulin with implications for traumatic brain injury and neurodegenerative disease. Am J Pathol (2010) 1.54
Cognitive decline in Alzheimer's disease is associated with selective changes in calcineurin/NFAT signaling. J Neurosci (2009) 1.54
Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. J Neurochem (2011) 1.53
University of Kentucky Sanders-Brown healthy brain aging volunteers: donor characteristics, procedures and neuropathology. Curr Alzheimer Res (2012) 1.52
Blood serum miRNA: non-invasive biomarkers for Alzheimer's disease. Exp Neurol (2011) 1.49
Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain (2012) 1.49
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci (2007) 1.48
Anti-Argonaute RIP-Chip shows that miRNA transfections alter global patterns of mRNA recruitment to microribonucleoprotein complexes. RNA (2009) 1.45
APOE ε4 increases risk for dementia in pure synucleinopathies. JAMA Neurol (2013) 1.41
Androgen cell signaling pathways involved in neuroprotective actions. Horm Behav (2007) 1.28
Targeting astrocytes ameliorates neurologic changes in a mouse model of Alzheimer's disease. J Neurosci (2012) 1.27
CSF1R mutations link POLD and HDLS as a single disease entity. Neurology (2013) 1.27
CD33 Alzheimer's risk-altering polymorphism, CD33 expression, and exon 2 splicing. J Neurosci (2013) 1.21
Focus on RNA isolation: obtaining RNA for microRNA (miRNA) expression profiling analyses of neural tissue. Biochim Biophys Acta (2008) 1.19
A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer's disease, dementia with lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls. J Alzheimers Dis (2013) 1.18
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17
Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J Alzheimers Dis (2009) 1.17
BACE1 and BACE2 enzymatic activities in Alzheimer's disease. J Neurochem (2009) 1.16
Arteriolosclerosis that affects multiple brain regions is linked to hippocampal sclerosis of ageing. Brain (2013) 1.13
Neuroinflammatory phenotype in early Alzheimer's disease. Neurobiol Aging (2012) 1.13
Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle. Proc Natl Acad Sci U S A (2002) 1.11
Management of patients with schwannomatosis: report of six cases and review of the literature. Surg Neurol (2004) 1.10
Peripherally expressed neprilysin reduces brain amyloid burden: a novel approach for treating Alzheimer's disease. J Neurosci Res (2009) 1.08
Frontal cortex neuropathology in dementia pugilistica. J Neurotrauma (2012) 1.08
Expression of neprilysin in skeletal muscle reduces amyloid burden in a transgenic mouse model of Alzheimer disease. Mol Ther (2009) 1.07
Epigenetic silencing of nucleolar rRNA genes in Alzheimer's disease. PLoS One (2011) 1.07
MicroRNAs in CNS injury: potential roles and therapeutic implications. Bioessays (2011) 1.05
The MAPT H1 haplotype is associated with tangle-predominant dementia. Acta Neuropathol (2012) 1.05
Individual microRNAs (miRNAs) display distinct mRNA targeting "rules". RNA Biol (2010) 1.04
Prediction of preclinical Alzheimer's disease: longitudinal rates of change in cognition. J Alzheimers Dis (2011) 1.03
Relationship between Serum and Brain Carotenoids, α-Tocopherol, and Retinol Concentrations and Cognitive Performance in the Oldest Old from the Georgia Centenarian Study. J Aging Res (2013) 1.03
Mild cognitive impairment: statistical models of transition using longitudinal clinical data. Int J Alzheimers Dis (2012) 1.01
Circulating microRNAs in Alzheimer's disease: the search for novel biomarkers. Front Mol Neurosci (2013) 1.01
Effects of short-term Western diet on cerebral oxidative stress and diabetes related factors in APP x PS1 knock-in mice. J Neurochem (2008) 1.00
Early brain injury alters the blood-brain barrier phenotype in parallel with β-amyloid and cognitive changes in adulthood. J Cereb Blood Flow Metab (2012) 1.00
Widespread suppression of huntingtin with convection-enhanced delivery of siRNA. Exp Neurol (2011) 1.00
Alzheimer disease pathology in subjects without dementia in 2 studies of aging: the Nun Study and the Adult Changes in Thought Study. J Neuropathol Exp Neurol (2011) 0.99
Preclinical AD Workgroup staging: pathological correlates and potential challenges. Neurobiol Aging (2011) 0.99
Optimizing gene expression analysis in archival brain tissue. Neurochem Res (2002) 0.98
Induction of ketosis may improve mitochondrial function and decrease steady-state amyloid-beta precursor protein (APP) levels in the aged dog. Brain Res (2008) 0.97
Adjusting for mortality when identifying risk factors for transitions to mild cognitive impairment and dementia. J Alzheimers Dis (2013) 0.97
Presenilin regulates capacitative calcium entry dependently and independently of gamma-secretase activity. Biochem Biophys Res Commun (2004) 0.97
Digital pathology and image analysis for robust high-throughput quantitative assessment of Alzheimer disease neuropathologic changes. J Neuropathol Exp Neurol (2012) 0.96
Effects of nonsteroidal anti-inflammatory drugs on amyloid-beta pathology in mouse skeletal muscle. Neurobiol Dis (2010) 0.96
BACE2 expression increases in human neurodegenerative disease. Am J Pathol (2011) 0.95
Balamuthia mandrillaris meningoencephalitis: survival of a pediatric patient. Pediatrics (2010) 0.95
Preclinical Alzheimer disease: brain oxidative stress, Abeta peptide and proteomics. Neurobiol Dis (2010) 0.93
Circulating neprilysin clears brain amyloid. Mol Cell Neurosci (2010) 0.92
Cognitive impairment in humanized APP×PS1 mice is linked to Aβ(1-42) and NOX activation. Neurobiol Dis (2011) 0.91
Oxidative modification of lipoic acid by HNE in Alzheimer disease brain. Redox Biol (2013) 0.91
Increased epitope-specific CD8+ T cells prevent murine coronavirus spread to the spinal cord and subsequent demyelination. J Virol (2005) 0.90
Effects of aging and genotype on circadian rhythms, sleep, and clock gene expression in APPxPS1 knock-in mice, a model for Alzheimer's disease. Exp Neurol (2012) 0.90
"End-stage" neurofibrillary tangle pathology in preclinical Alzheimer's disease: fact or fiction? J Alzheimers Dis (2011) 0.90
Pittsburgh compound B and the postmortem diagnosis of Alzheimer disease. Ann Neurol (2012) 0.89
Impairment of proteostasis network in Down syndrome prior to the development of Alzheimer's disease neuropathology: redox proteomics analysis of human brain. Biochim Biophys Acta (2013) 0.89
Amyloid-beta peptide and oligomers in the brain and cerebrospinal fluid of aged canines. J Alzheimers Dis (2010) 0.89
In vitro and in vivo degradation of Abeta peptide by peptidases coupled to erythrocytes. Peptides (2007) 0.88
Synergistic effects of long-term antioxidant diet and behavioral enrichment on beta-amyloid load and non-amyloidogenic processing in aged canines. J Neurosci (2010) 0.87
Studying microRNAs in the brain: technical lessons learned from the first ten years. Exp Neurol (2011) 0.87
Self-reported head injury and risk of late-life impairment and AD pathology in an AD center cohort. Dement Geriatr Cogn Disord (2013) 0.86
17β-estradiol and progesterone regulate expression of β-amyloid clearance factors in primary neuron cultures and female rat brain. Endocrinology (2012) 0.85
Neuron specific toxicity of oligomeric amyloid-β: role for JUN-kinase and oxidative stress. J Alzheimers Dis (2010) 0.85
Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease. Neurobiol Dis (2010) 0.85
Biomarkers and evolution in Alzheimer disease. Prog Neurobiol (2011) 0.84
RNA oxidation adducts 8-OHG and 8-OHA change with Aβ42 levels in late-stage Alzheimer's disease. PLoS One (2011) 0.84
Postmortem Pittsburgh Compound B (PiB) binding increases with Alzheimer's disease progression. J Alzheimers Dis (2012) 0.83
Immunization with fibrillar Abeta(1-42) in young and aged canines: Antibody generation and characteristics, and effects on CSF and brain Abeta. Vaccine (2006) 0.83
Leptin regulates amyloid β production via the γ-secretase complex. Biochim Biophys Acta (2012) 0.83
APP(DeltaNL695) expression in murine tissue downregulates CNBP expression. Neurosci Lett (2010) 0.82
Dysregulation of the mitogen granulin in human cancer through the miR-15/107 microRNA gene group. Cancer Res (2010) 0.82
Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis. Biochim Biophys Acta (2013) 0.81
A combination cocktail improves spatial attention in a canine model of human aging and Alzheimer's disease. J Alzheimers Dis (2012) 0.81
β-Secretases, Alzheimer's Disease, and Down Syndrome. Curr Gerontol Geriatr Res (2012) 0.81
Primary central nervous system angiitis, amyloid angiopathy, and Alzheimer's pathology presenting with Balint's syndrome. Surv Ophthalmol (2004) 0.81
Gamma-secretase: substrates and inhibitors. Mol Neurobiol (2002) 0.80
Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options. Neurodegener Dis Manag (2011) 0.80
Aβ aggregation profiles and shifts in APP processing favor amyloidogenesis in canines. Neurobiol Aging (2010) 0.80
Hippocampal Sclerosis of Aging Can Be Segmental: Two Cases and Review of the Literature. J Neuropathol Exp Neurol (2015) 0.80
Purified high molecular weight synthetic Aβ(1-42) and biological Aβ oligomers are equipotent in rapidly inducing MTT formazan exocytosis. Neurosci Lett (2011) 0.79
Prolonged diet induced obesity has minimal effects towards brain pathology in mouse model of cerebral amyloid angiopathy: implications for studying obesity-brain interactions in mice. Biochim Biophys Acta (2013) 0.78
The effect of cigarette smoking on functional recovery following peripheral nerve ischemia/reperfusion injury. Microsurgery (2010) 0.77
Assessing the discriminant ability, reliability, and comparability of multiple short forms of the Boston Naming Test in an Alzheimer's disease center cohort. Dement Geriatr Cogn Disord (2015) 0.76
Coenzyme Q10 and cognition in atorvastatin treated dogs. Neurosci Lett (2011) 0.76
Efficient activation of reconstructed rat embryos by cyclin-dependent kinase inhibitors. PLoS One (2010) 0.75